Stock Events

Stock Events

BioStem Technologies 

€0.9680
20
-€0.12-11.19% 08:55 Today

Statistics

Day High
0.971
Day Low
0.968
52W High
4.39
52W Low
0.968
Volume
-
Avg. Volume
-
Mkt Cap
18.07M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 12Expected
Q1 2026
Q2 2026
Next
-0.45
-0.38
-0.31
-0.24
Expected EPS
-0.3854305
Actual EPS
N/A

Financials

-11.61%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
45.53MRevenue
-5.28MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0JQ.F. It's not an investment recommendation.
Alphabet
7
GOOGL
Amazon
6
AMZN
NVIDIA
5
NVDA
Tesla
3
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is a global pharmaceutical company that competes with BioStem Technologies in the development and commercialization of medications and therapies, including those in the regenerative medicine space.
Novartis
NVS
Mkt Cap303.67B
Novartis is a multinational pharmaceutical company that competes in various therapeutic areas, including those related to BioStem's focus on regenerative medicine and pharmaceuticals.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is involved in the research and development of innovative therapeutics in areas overlapping with BioStem's interests, particularly in cell therapy and regenerative medicine.
AMGEN
AMGN
Mkt Cap251.94B
Amgen is a biotechnology company focusing on human therapeutics, competing with BioStem in the development of treatments in areas such as regenerative medicine.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments that could compete with BioStem's regenerative medicine and pharmaceutical products.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals engages in creating new possibilities in medicine, including gene editing and therapy, areas that are potentially competitive with BioStem's regenerative medicine focus.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is known for its innovative biopharmaceuticals, directly competing with BioStem in the development of regenerative and cell-based therapies.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is at the forefront of developing gene-based therapies, directly competing with BioStem in the innovative therapeutic space, including regenerative medicine.

About

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
Show More
CEO
Jason Matuszewski
Employees
2
Country
United States
ISIN
US0906842002
WKN
000A14M3B

Listings

F
DE
0JQ.F
XNAS
US
BSEM

0 Comments

Share your thoughts

FAQs

What is BioStem Technologies stock price today?▼
The current price of 0JQ.F is €0.97 EUR — it has decreased by -11.19% in the past 24 hours. Watch BioStem Technologies stock price performance more closely on the chart.
What is BioStem Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange BioStem Technologies stocks are traded under the ticker 0JQ.F.
What is BioStem Technologies market cap?▼
Today BioStem Technologies has the market capitalization of 18.07M
When is the next BioStem Technologies earnings date?▼
BioStem Technologies is going to release the next earnings report on November 12, 2026.
What were BioStem Technologies earnings last quarter?▼
0JQ.F earnings for the last quarter are -0.45 EUR per share, whereas the estimation was -0.43 EUR resulting in a -4% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is BioStem Technologies revenue for the last year?▼
BioStem Technologies revenue for the last year amounts to 45.53M EUR.
What is BioStem Technologies net income for the last year?▼
0JQ.F net income for the last year is -5.28M EUR.
How many employees does BioStem Technologies have?▼
As of November 2, 2026, the company has 2 employees.
In which sector is BioStem Technologies located?▼
BioStem Technologies operates in the Health & Wellness sector.
When did BioStem Technologies complete a stock split?▼
The last stock split for BioStem Technologies was on January 27, 2015 with a ratio of 1:400.
Where is BioStem Technologies headquartered?▼
BioStem Technologies is headquartered in POMPANO BEACH, United States.